Transneural wins MJFF grant to study Parkinson’s candidate TN-001

Transneural Therapeutics has received research funding from The Michael J. Fox Foundation to test TN-001 in preclinical Parkinson’s disease models. The work will focus on 5-HT2A and 5-HT2C serotonin receptor signaling, with an emphasis on non-motor symptoms and disease biology.

Why it matters: - Parkinson’s disease treatments still leave major gaps, especially for non-motor symptoms such as psychiatric effects. - The Michael J. Fox Foundation grant gives Transneural a funded path to test whether TN-001 can do more than ease symptoms and may help alter disease biology. - The award also adds external support for a mechanism-focused approach targeting 5-HT2A and 5-HT2C serotonin receptors.

What happened: - Transneural Therapeutics said Oct. 13, 2026, that The Michael J. Fox Foundation for Parkinson’s Research awarded the company a research grant. - The grant will support studies of TN-001 in preclinical models of Parkinson’s disease. - The project will examine the role of 5-HT2A/5-HT2C serotonin receptor signaling in Parkinson’s disease. - The grant was awarded through MJFF’s Accelerating Biological Understanding and Translational Approaches for Parkinson’s Disease initiative.

The details: - Transneural said TN-001 has shown rapid, statistically significant increases in structural neuroplasticity and synaptogenesis in preclinical studies. - The study will look at whether TN-001 can influence alpha-synuclein pathology and other disease-related biological measures. - The research will use a validated mouse model of Parkinson’s disease. - The project will focus on psychiatric and other non-motor symptoms, which MJFF described as an understudied part of Parkinson’s disease. - TN-001 is described by Transneural as a dual 5-HT2A partial agonist, 5-HT2B antagonist and 5-HT2C agonist. - Transneural said TN-001 was designed for rapid and robust efficacy with a cardiac safety profile intended to support daily at-home dosing. - The company said TN-001 is being developed for depression, post-traumatic stress disorder and Parkinson’s disease. - Transneural said its pipeline is focused on G-protein coupled receptors and uses AI-informed chemistry plus medicinal chemistry. - The company said it holds an exclusive license from Yale University to develop and commercialize pipeline assets.

Between the lines: - The grant suggests MJFF sees enough promise in the receptor hypothesis to back a preclinical program built around it. - The work also reflects a broader push in Parkinson’s research to understand non-motor symptoms, not just movement-related ones. - Transneural is positioning TN-001 as a potentially disease-modifying therapy, but the current evidence cited is preclinical.

What's next: - Transneural and MJFF-supported researchers will test TN-001 in preclinical Parkinson’s models. - The studies are expected to clarify whether 5-HT2A and 5-HT2C agonism can affect symptoms, disease processes or both. - Results from the mouse-model work could shape whether TN-001 advances further in Parkinson’s development.

The bottom line: - The grant gives Transneural outside validation and funding to probe whether TN-001 can become more than a symptomatic therapy for Parkinson’s disease.